Overview

QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Status:
Active, not recruiting

Trial end date:
2021-04-01

Target enrollment:

Participant gender:

Summary

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care first line therapy and chemotherapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

ImmunityBio, Inc.
NantCell, Inc.

Treatments:

Avelumab
Bevacizumab
Capecitabine
Cyclophosphamide
Fluorouracil
Leucovorin
Oxaliplatin
Paclitaxel
Vaccines